Amundi’s Nuvation Bio NUVB Stock Holding History

Amundi’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$155K	Buy	36,072 +23,258	+182%	+$130K	﹤0.01%	1917
2025 Q4	$115K	Buy	+12,814	New	+$79.4K	﹤0.01%	1805

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amundi's NUVB Position: Q1 2026 in Review

Amundi increased its Nuvation Bio (NUVB) stake by 182% in Q1 2026, buying an estimated $130K and bringing the position to 36,072 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Amundi first reported a position in NUVB in Q4 2025 and has held it in 2 quarters since. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

Amundi held 36,072 shares of Nuvation Bio worth $155K as of Q1 2026.
Amundi bought 23,258 Nuvation Bio shares in Q1 2026, an estimated $130K.
Nuvation Bio made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1917 holding.
Amundi first reported a position in Nuvation Bio in Q4 2025 and has held it in 2 quarters since.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.